This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
To the Editor:—
The recent report before the American Chemical Society meeting of the details of synthesis of a series of sulfanilamide derivatives by Crossley, Northey and Hultquist (Sulfanilamide Derivatives: I. Amino-Aryl-Sulfonamido-Aryl-Sulfonic Acids and Amino-Aryl-Sulfonamino-Aryl-Carboxylic Acids; II. Disulfanilamide and Related Compounds; III. Strepto-N-Polysulfanilyl-Sulfanilamides and Related Compounds, J. Am. Chem. A., to be published) together with the statement that they have been found to be effective protective agents in experimental infections with influenza virus makes us feel that some of the preliminary experimental work on which these statements are based should be presented to the members of the medical profession for critical analysis.A series of almost 100 sulfanilamide derivatives have been subjected to preliminary examination for protective action in experimental influenza virus infections. The Puerto Rico strain of human influenza virus, originally obtained from Dr. Francis of the Rockefeller Institute for Medical Research, was employed throughout the entire series. The
Climenko DR, Crossley ML, Northey EH. THE PROTECTIVE ACTION OF CERTAIN SULFANILAMIDE DERIVATIVES IN EXPERIMENTAL INFLUENZA INFECTIONS. JAMA. 1938;110(25):2099–2100. doi:10.1001/jama.1938.02790250059025
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: